Boditech Med
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Boditech Med makes rapid diagnostic test cartridges and the handheld reader devices that run them, allowing clinicians to test for infections, cardiovascular conditions, hormonal disorders, cancer markers, and other diseases at the point of care rather than sending samples to a central lab.
Its products are used by hospitals, clinics, and other health-care providers, and it ships to over a hundred countries worldwide. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company operates two distinct business lines: the single-use test cartridges and the diagnostic reader instruments that process them.
Summary is AI-generated and may contain errors · figures from DART filings
Boditech Med in five facts
What does Boditech Med do?
Boditech Med makes rapid diagnostic test cartridges and the handheld reader devices that run them, allowing clinicians to test for infections, cardiovascular conditions, hormonal disorders, cancer markers, and other diseases at the point of care rather than sending samples to a central lab.
Where is Boditech Med listed and in which sector?
Boditech Med (Korean name: 바디텍메드) trades under KRX code 206640 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Boditech Med?
Its market capitalisation was US$147.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Boditech Med's latest annual revenue and operating profit?
For fiscal year 2025, Boditech Med reported revenue of US$122.3M, operating profit of US$21.8M and net income of US$18M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 17.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Share cancellation decisionSep 22
- Treasury share trust terminated: results reportSep 22
- Material event report (treasury share trust terminated)Sep 22
- Operating results (consolidated) (preliminary) (fair disclosure)
Boditech Med filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$35.5M (+21.54% year on year), operating profit of US$5.8M (−10.45% year on year) and net income of US$5.21M (−0.7% year on year).
Earnings · Jul 30 - Operating results (consolidated) (preliminary) (fair disclosure)
Boditech Med filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$29.5M (+9.58% year on year), operating profit of US$4.68M (−15.79% year on year) and net income of US$6.53M (+30.85% year on year).
Earnings · May 8 - Operating results (consolidated) (preliminary) (fair disclosure)
Boditech Med filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$28.7M (+32.88% year on year), operating profit of US$3.49M (+134.05% year on year) and net income of US$953K (−71.44% year on year).
Earnings · Feb 20 - Cash/in-kind dividend decision
Boditech Med declared a cash dividend of US$0.10 per share.
Dividend · Feb 20 - Treasury share disposal: results reportTreasury Shares · Feb 11
- Material event report (treasury share disposal)
Boditech Med disclosed a plan to sell treasury shares worth US$4.22K, about 0.0% of its market value.
Treasury Shares · Feb 10 - Treasury share disposal: results reportTreasury Shares · Jan 9
- Material event report (treasury share disposal)Treasury Shares · Jan 6